Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $6.94 in the prior trading day, Relay Therapeutics Inc (NASDAQ: RLAY) closed at $6.86, down -1.15%. In other words, the price has decreased by -$1.15 from its previous closing price. On the day, 2.31 million shares were traded. RLAY stock price reached its highest trading level at $7.035 during the session, while it also had its lowest trading level at $6.77.
Ratios:
Our goal is to gain a better understanding of RLAY by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 20.92 and its Current Ratio is at 20.92. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $4.
Jefferies Upgraded its Hold to Buy on September 10, 2024, whereas the target price for the stock was revised from $10.60 to $16.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 03 ’25 when Patel Sanjiv sold 62,073 shares for $7.00 per share. The transaction valued at 434,511 led to the insider holds 703,215 shares of the business.
Rahmer Peter sold 21,394 shares of RLAY for $160,455 on Oct 29 ’25. The insider now owns 337,469 shares after completing the transaction at $7.50 per share. On Oct 28 ’25, another insider, Rahmer Peter, who serves as the insider of the company, sold 19,135 shares for $7.29 each. As a result, the insider received 139,494 and left with 358,863 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 1182742272 and an Enterprise Value of 560150272. For the stock, the TTM Price-to-Sale (P/S) ratio is 141.48 while its Price-to-Book (P/B) ratio in mrq is 1.77. Its current Enterprise Value per Revenue stands at 67.044 whereas that against EBITDA is -1.668.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.52, which has changed by 0.11039996 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $7.64, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is 27.49%, while the 200-Day Moving Average is calculated to be 76.31%.
Shares Statistics:
The stock has traded on average 1.69M shares per day over the past 3-months and 2175150 shares per day over the last 10 days, according to various share statistics. A total of 171.69M shares are outstanding, with a floating share count of 130.25M. Insiders hold about 24.46% of the company’s shares, while institutions hold 78.54% stake in the company. Shares short for RLAY as of 1760486400 were 21928192 with a Short Ratio of 12.99, compared to 1757894400 on 22504700. Therefore, it implies a Short% of Shares Outstanding of 21928192 and a Short% of Float of 15.43.
Earnings Estimates
Relay Therapeutics Inc (RLAY) is presently subject to a detailed evaluation by 8.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.05 and low estimates of -$0.53.
Analysts are recommending an EPS of between -$1.23 and -$2.14 for the fiscal current year, implying an average EPS of -$1.7. EPS for the following year is -$1.75, with 7.0 analysts recommending between -$1.24 and -$2.67.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for RLAY’s current fiscal year. The highest revenue estimate was $38.4M, while the lowest revenue estimate was $8.36M, resulting in an average revenue estimate of $12.97M. In the same quarter a year ago, actual revenue was $10.01M
